Intellectual Property

CVD faculty have developed technology resulting in 26 U.S. patents on vaccines, diagnostics and drug delivery systems.

Some examples are:

• Fasano A, Levine M, Nataro J, Noriega F: Antibodies having binding specificity to ShET2, an enterotoxin of Shigella flexneri 2a (U.S. Patent 5,686,580).
• Noriega F, Levine M: Gua mutants of Shigella spp. And vaccines containing the same (U.S. Patent 5,783,196).
• Fasano A: Zonula occludens toxin receptor (U.S. Patents 5,864,014, 5,912,323, and 5,948,629).
• Kaper JB, Levine M: Vibrio cholerae O1 (CVD111) and non-O1 (CVD112 and CVD112RM) serogroup vaccine strains, method of making same, and products derived thereof (U.S. Patent 5,882,653).
• Noriega FR, Levine MM, Sztein MB: Attenuated mutants of Salmonella which constitutively express the Vi antigen (U.S. Patent 6,190,669).
• Kaper JB, Jarvis K: Immunodiagnostic test for enterohemorrhagic Escherichia coli infection (U.S. Patent 6,204,004).
• Galen JE: Expression plasmids (U.S. Patent 6,413,768).
• Fasano A: Peptide antagonists of zonulin and methods for use of the same (U.S. Patent 6,548,925).

For further information concerning licensing CVD intellectual technology, please view the website of the University of Maryland Office of Research and Development.